Results from Antaros Medical’s liver imaging method study have recently been published in the manuscript “The Combination of MR Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis” in the Journal of Magnetic Resonance Imaging. The study has been performed as a collaboration between Antaros Medical, Uppsala University and Boehringer Ingelheim. The results from the study further underline the value of MRI in metabolic dysfunction-associated steatotic liver disease (MASLD; previously called non-alcoholic fatty liver disease or NAFLD). The study shows that MR-based biomarkers predict which subjects will be diagnosed with metabolic dysfunction-associated steatohepatitis (MASH; previously called non-alcoholic steatohepatitis or NASH) on biopsy and can differentiate between no or mild fibrosis and moderate and higher stages of fibrosis. Combining liver stiffness (measured with MRE) and liver fat (measured with MRI-PDFF) further improves the diagnosis of MASH.
Find the publication here:
Authors: Alsaqal S, Hockings P, Ahlström H, Gummesson A, Hedström A, Hulthe J, Johansson L, Niessen H G, Schoelch C, Schultheis C, Vessby J, Wanders A, Rorsman F, Ebeling Barbier C
About MASLD
MASLD affects around 25-30% of the adult population worldwide. The disease is associated with an increased risk of advanced fibrosis, cirrhosis, and liver-related mortality. It is crucial to understand disease progression and severity for both clinical management and clinical research. Today, liver biopsy is used for disease stratification but is limited by cost and risks. MRI biomarkers have emerged as key non-invasive alternatives to accurately detect hepatic steatosis and liver fibrosis and could potentially be used to identify the progressive form of MASH.